Preliminary safety and dosimetry results from the 36-patient lead-in of Telix’s Phase 3 ProstACT Global study will be delivered as a late-breaking oral at ASCO 2026. The dataset covers tolerability, biodistribution, and organ dose estimates for TLX591-Tx, a PSMA-targeted lutetium-177 radioconjugate, administered with standard of care in PSMA-positive metastatic castration-resistant prostate cancer. No efficacy outcomes are being disclosed ahead of the session.
The core development is Telix advancing an antibody-based radiotherapeutic into a two-part, international Phase 3 program that pits TLX591-Tx plus standard of care against standard of care alone. Part 1, now complete, informs dose, schedule, and safety management. Part 2 expands globally in a 2:1 randomization with a planned enrollment of about 490 patients who have progressed on one androgen receptor pathway inhibitor and are selected by PSMA PET imaging using 68Ga-PSMA-11 agents. The company has framed the trial to mirror routine practice and enable broad geographic uptake if successful, with imaging eligibility harmonized to widely available tracers.
Strategically, this is a differentiation play in a PSMA radioligand market defined to date by small-molecule agents. An antibody chassis changes pharmacokinetics, with hepatic clearance and lower renal and salivary gland exposure expected relative to small molecules. If borne out, that profile could shift the safety trade-off from xerostomia and renal handling toward a hematologic or hepatic monitoring paradigm more familiar to antibody-based therapies. It also positions Telix to leverage its installed imaging footprint while transitioning from diagnostics to therapeutics, a path that demands credible Phase 3 execution and reliable isotope supply. The choice of a standard-of-care control rather than an active PSMA comparator avoids head-to-head risk but heightens the need for clean safety and operationally simple dosing to justify adoption amid increasingly crowded treatment sequences.
For sites, the signal is twofold: a growing need to operationalize antibody radioconjugates alongside small-molecule RLTs, and the persistence of PSMA PET as a gatekeeper. The lead-in’s dosimetry readout will shape whether fixed-activity dosing or patient-specific dose optimization is mandated, which in turn drives staffing, physics support, and scheduling complexity. Infusion logistics for an antibody conjugate, nuclear pharmacy capacity for 177Lu handling, and coordinated lab monitoring will be critical to scaling Part 2 and, eventually, commercial practice. CROs and sponsors will be watching for how the protocol manages marrow exposure and retreatment intervals, as these factors influence screen failure rates, cycle adherence, and AE-driven discontinuations. Regulators continue to scrutinize radiopharmaceutical safety with an emphasis on organ dose constraints, hematologic toxicity, and long-term secondary malignancy risk; robust, prospectively collected dosimetry data in a Phase 3 setting can de-risk interactions.
The broader market context matters. As payers and clinicians parse sequencing across ARPIs, taxanes, PARP combinations, and PSMA therapies, assets that can reduce off-target toxicities without adding operational friction stand to gain. However, a standard-of-care control arm will limit direct comparative claims against incumbent PSMA agents, placing pressure on secondary endpoints, patient-reported outcomes, and health resource utilization to articulate value. Manufacturing scalability of both the antibody conjugate and lutetium-177, as well as geographic isotope availability, remains a practical gating factor for rapid uptake if the trial succeeds.
What to watch at ASCO: rates of grade 3 or higher hematologic events, any signal of renal or salivary adverse effects consistent with the antibody’s pharmacology, organ dose distributions that inform outpatient feasibility, and the proportion of patients completing planned cycles without dose modification. Equally important will be clarity on Part 2 timelines, geographic site activation, any move toward adaptive dosing based on dosimetry, and whether the imaging eligibility can flex to local tracer availability without undermining consistency. The readout will not settle efficacy, but it will determine whether Telix’s differentiation thesis has enough safety headroom and operational simplicity to warrant the Phase 3 expansion at pace.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
